Adam Franchi v. Spring Bank Pharmaceuticals, Inc. et al: Class Action Complaint

Class Action Complaint alleging violations of the Securities Exchange Act in Adam Franchi v. Spring Bank Pharmaceuticals, Inc., of Massachusetts, described as “a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform” whose shares are listed on NASDAQ; David Arkowitz, Todd Brady, Timothy Clackson, Martin Driscoll, Kurt M. Eichler, Pamela Klein, Scott Smith, and F-star Therpaeutics Limited, of England, at the U. S. District Court for the District of Delaware.